Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | The safety and efficacy of parsaclisib in autoimmune hemolytic anemia

Ulrich Jäger • 10 Jun 2022
EHA 2022
Anemias Autoimmune Hemolytic Anemia Cold Agglutinin Disease Non-Malignant Parsaclisib

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the results of a study evaluating the safety and efficacy of parsaclisib for the treatment of warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries
1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy
0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
3:10
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Ulrich Jäger • 8 Dec 2025
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
1:54
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
Ulrich Jäger • 2 Dec 2025
Exciting and potentially practice-changing hemophilia updates from ASH 2025
1:59
Exciting and potentially practice-changing hemophilia updates from ASH 2025
Ulrich Jäger • 12 Dec 2025
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
2:51
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
Ulrich Jäger • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals